NZ581259A - Modulators of cystic fibrosis transmembrane conductance regulator - Google Patents

Modulators of cystic fibrosis transmembrane conductance regulator

Info

Publication number
NZ581259A
NZ581259A NZ581259A NZ58125908A NZ581259A NZ 581259 A NZ581259 A NZ 581259A NZ 581259 A NZ581259 A NZ 581259A NZ 58125908 A NZ58125908 A NZ 58125908A NZ 581259 A NZ581259 A NZ 581259A
Authority
NZ
New Zealand
Prior art keywords
disease
hereditary
type
cystic fibrosis
compounds
Prior art date
Application number
NZ581259A
Other languages
English (en)
Inventor
Ruah Sara Hadida
Peter D Grootenhuis
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NZ581259A publication Critical patent/NZ581259A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
NZ581259A 2007-05-09 2008-05-09 Modulators of cystic fibrosis transmembrane conductance regulator NZ581259A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92833407P 2007-05-09 2007-05-09
PCT/US2008/063144 WO2008141119A2 (en) 2007-05-09 2008-05-09 Modulators of cftr

Publications (1)

Publication Number Publication Date
NZ581259A true NZ581259A (en) 2012-07-27

Family

ID=39847000

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ581259A NZ581259A (en) 2007-05-09 2008-05-09 Modulators of cystic fibrosis transmembrane conductance regulator

Country Status (8)

Country Link
US (2) US8969386B2 (enExample)
EP (2) EP2164840A2 (enExample)
JP (4) JP5497633B2 (enExample)
CN (3) CN104447716A (enExample)
AU (1) AU2008251504B2 (enExample)
CA (1) CA2686838C (enExample)
NZ (1) NZ581259A (enExample)
WO (1) WO2008141119A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
JP5143738B2 (ja) 2005-08-11 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節物質
DK1945632T3 (da) 2005-11-08 2013-12-16 Vertex Pharma Heterocycliske modulatorer af ATP-bindende kassettetransportører
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
DK2578571T3 (en) 2007-11-16 2015-10-05 Vertex Pharma Isoquinoline modulators of ATP binding cassette transporters
DK2639222T3 (en) 2007-12-07 2016-10-03 Vertex Pharma Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
WO2009108657A2 (en) * 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
AU2009231993B2 (en) * 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
ES2654414T3 (es) 2009-03-20 2018-02-13 Vertex Pharmaceuticals Incorporated Proceso de preparación de moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
WO2013038381A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) * 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
LT2806859T (lt) 2012-01-25 2019-10-25 Vertex Pharma 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
JP2015530997A (ja) * 2012-08-21 2015-10-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規ピリジン誘導体
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
HRP20221389T1 (hr) * 2013-10-18 2023-01-06 Celgene Quanticel Research, Inc. Inhibitori bromodomena
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
MX374758B (es) 2013-12-13 2025-03-06 Hoffmann La Roche Inhibidores de tirosina cinasa de bruton.
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
KR102788925B1 (ko) 2014-10-31 2025-04-02 애브비 에스.에이.알.엘. 치환된 크로만 및 이의 사용 방법
SI3221692T1 (sl) 2014-11-18 2021-11-30 Vertex Pharmaceuticals Inc. Postopek za izvajanje testov visoke prepustnosti z visoko zmogljivostno tekočinsko kromatografijo
JP2017178795A (ja) * 2016-03-28 2017-10-05 富士ゼロックス株式会社 化合物、光電変換デバイス、電子写真感光体、プロセスカートリッジ、及び画像形成装置
CN108658851B (zh) * 2017-03-27 2023-06-06 山东特珐曼药业有限公司 2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
CN112341416A (zh) * 2019-08-09 2021-02-09 天津津艺医药科技发展有限责任公司 一种制备苯并含氧脂杂环衍生物的方法
CA3179182A1 (en) * 2020-04-02 2021-10-07 Horizon Therapeutics Ireland Dac Methods of treating systemic sclerosis
JP2023529311A (ja) * 2020-05-27 2023-07-10 アリエル プレシジョン メディスン、インク． Ｃｆｔｒ関連疾患および障害を治療する方法
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN113881728B (zh) * 2021-09-30 2023-12-15 深圳瑞德林生物技术有限公司 7-氨甲基-7-脱氮鸟嘌呤(PreQ1)的制备方法
CA3251849A1 (en) 2022-03-02 2023-09-07 Horizon Therapeutics Ireland Dac METHOD FOR MANUFACTURING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST
WO2024072793A1 (en) * 2022-09-26 2024-04-04 Rectify Pharmaceuticals, Inc. Pyridine carboxamide compounds and their use in treating medical conditions

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3758475A (en) 1971-07-20 1973-09-11 Sandoz Ag Pyrido(2,3-d)pyrimidin 2 ones
DE3263567D1 (en) 1981-12-14 1985-06-20 Medea Res Srl New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
IT1226048B (it) 1981-12-14 1990-12-10 Medea Res Srl Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5981714A (en) 1990-03-05 1999-11-09 Genzyme Corporation Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja) 1990-11-27 2001-05-21 武田薬品工業株式会社 ピリドピリダジン誘導体およびその用途
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
CA2107196A1 (en) 1992-09-29 1994-03-30 Mitsubishi Chemical Corporation Carboxamide derivatives
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
AU688811B2 (en) 1993-10-21 1998-03-19 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
DE4405712A1 (de) 1994-02-23 1995-08-24 Basf Ag Substituierte Naphthyridine und deren Verwendung
NO305987B1 (no) 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
WO1996010027A1 (en) 1994-09-27 1996-04-04 Janssen Pharmaceutica N.V. N-substituted piperidinyl bicyclic benzoate derivatives
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
EP0891334A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU4159297A (en) 1996-08-23 1998-03-06 Agouron Acquisition Corp. Neuropeptide-y ligands
AU6013998A (en) 1996-12-30 1998-07-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5948814A (en) 1997-02-20 1999-09-07 The Curators Of The University Of Missouri Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
NZ503712A (en) 1997-10-02 2003-07-25 Sankyo Co Amidopropionic acid derivatives
DK1054996T3 (da) 1998-02-17 2004-05-24 Searle & Co Fremgangsmåde til den enzymatiske adskillelse af lactamer
KR20010052587A (ko) 1998-06-08 2001-06-25 둘락 노먼 씨. 뉴로펩티드 ｙ5 수용체 길항제
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
IL142768A0 (en) 1998-12-18 2002-03-10 Du Pont Pharm Co N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2364662C (en) 1999-02-24 2009-10-20 F. Hoffmann-La Roche Ag 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
ES2359235T3 (es) 1999-02-24 2011-05-19 F. Hoffmann-La Roche Ag Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1.
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1194417A1 (de) 1999-06-18 2002-04-10 Bayer Ag Phenoxyfluorpyrimidine
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en) 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2001233069A1 (en) 2000-01-28 2001-08-07 Biogen, Inc. Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. Inhibitors of factor xa
WO2001081317A1 (en) 2000-04-26 2001-11-01 Gliatech, Inc. Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
AU2000249828A1 (en) 2000-05-03 2001-11-12 Taisho Pharmaceutical Co. Ltd. Stat4 and stat6 binding dipeptide derivatives
CN1386118A (zh) 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
MXPA03002297A (es) 2000-09-15 2003-06-06 Vertex Pharma Compuestos de triazol utiles como inhibidores de proteina cinasa.
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
WO2002028348A2 (en) 2000-10-04 2002-04-11 The Children's Hospital Of Philadelphia Compositions and methods for treatment of cystic fibrosis
GB2367816A (en) 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
ATE269856T1 (de) 2000-10-20 2004-07-15 Merck Patent Gmbh Chirale binaphtol-verbindungen
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US6887996B2 (en) 2000-12-01 2005-05-03 Guilford Pharmaceuticals Inc. Compounds and their use
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
CA2442654A1 (en) 2001-04-10 2002-10-10 Transtech Pharma, Inc. Probes, systems, and methods for drug discovery
AU2002250876B2 (en) 2001-04-23 2005-03-03 F. Hoffmann-La Roche Ag Use of NK-1 receptor antagonists against benign prostatic hyperplasia
HUP0400316A2 (hu) 2001-05-22 2005-02-28 Neurogen Corporation CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
AU2002322585A1 (en) 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1411928A1 (en) 2001-07-20 2004-04-28 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja) 2001-11-19 2003-05-27 Toray Ind Inc 環状含窒素誘導体
JP2003221386A (ja) 2001-11-26 2003-08-05 Takeda Chem Ind Ltd 二環性誘導体、その製造法およびその用途
CN100506807C (zh) 2001-12-21 2009-07-01 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr) 2002-06-12 2005-03-11 Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
WO2004035571A1 (en) 2002-10-15 2004-04-29 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
EP1558576A4 (en) 2002-10-30 2008-04-16 Merck & Co Inc PIPERIDINYLCYCLOPENTYLARYLBENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTORACTIVITY
EP1569645A2 (en) 2002-12-12 2005-09-07 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
MXPA05008450A (es) 2003-02-10 2005-10-18 Vertex Pharma Procesos para la preparacion de n-heteroaril-n-aril-aminas mediante reaccion de un ester de acido n-aril-carbamico con un halo-heteroarilo y procesos analogos.
EP1601657A1 (en) 2003-03-12 2005-12-07 Vertex Pharmaceuticals Incorporated Pyrazole modulators of atp-binding cassette transporters
KR20060006953A (ko) 2003-04-30 2006-01-20 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 카르복실산
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EP1638505B1 (en) 2003-06-27 2012-04-25 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Amphiphilic pyridinium compounds, method of making and use thereof
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
JP2005053902A (ja) 2003-07-18 2005-03-03 Nippon Nohyaku Co Ltd フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
CA2537829A1 (en) 2003-09-05 2005-03-17 Neurogen Corporation Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
EP1680411A2 (en) 2003-10-08 2006-07-19 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
FR2861304B1 (fr) 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005049018A1 (en) 2003-11-14 2005-06-02 Vertex Pharmaceuticals Incorporated Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
WO2005049034A2 (en) 2003-11-19 2005-06-02 Glaxo Group Limited Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
AU2005210474B2 (en) 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7691860B2 (en) 2004-02-19 2010-04-06 Banyu Pharmaceutical Co., Ltd. Sulfonamide derivatives
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
US20080015196A1 (en) 2004-04-16 2008-01-17 Neurogen Corporation Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands
WO2005108358A2 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Pyrrolidine derivatives useful as bace inhibitors
US7585885B2 (en) 2004-04-22 2009-09-08 Eli Lilly And Company Pyrrolidine derivatives useful as BACE inhibitors
AU2005249154B2 (en) 2004-06-01 2011-02-10 Luminex Molecular Diagnostics, Inc. Method of detecting cystic fibrosis associated mutations
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
CA2572549A1 (en) 2004-07-01 2006-01-12 Warner-Lambert Company Llc Preparation of pharmaceutical compositions containing nanoparticles
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
EP1773797A2 (en) 2004-08-06 2007-04-18 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
WO2006037117A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
CA2581516C (en) 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
CA2587461A1 (en) 2004-11-15 2006-05-18 Pfizer Products Inc. Azabenzoxazoles for the treatment of cns disorders
ES2322487T3 (es) * 2004-12-15 2009-06-22 Dompe' Pha.R.Ma S.P.A. Derivados de acido 2-arilpropionico y composiciones farmaceuticas que los contienen.
JP4790260B2 (ja) 2004-12-22 2011-10-12 出光興産株式会社 アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
EP1844003A4 (en) 2005-01-27 2010-09-22 Astrazeneca Ab NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
US20090048258A1 (en) 2005-02-01 2009-02-19 Masaki Ogino Amide Compound
EP2363128B1 (en) 2005-03-11 2016-02-17 Vertex Pharmaceuticals Incorporated Indole modulators of ATP-binding cassette transporters
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
JP2008536950A (ja) 2005-04-18 2008-09-11 ニューロジェン・コーポレーション 置換ヘテロアリールのｃｂ１拮抗薬
AU2006236155A1 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
EP1891018B1 (en) 2005-05-24 2011-11-16 Vertex Pharmaceuticals, Inc. Modulators of atp-binding cassette transporters
EP1890694A4 (en) 2005-06-02 2010-10-27 Bayer Cropscience Ag SUBSTITUTED PHENYLALKYL HETEROARYL DERIVATIVES
EP1919875A2 (en) 2005-06-21 2008-05-14 Astex Therapeutics Limited Pyrazole derivatives and their use as pka and pkb modulators
ZA200802172B (en) 2005-08-11 2009-06-24 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
JP5143738B2 (ja) 2005-08-11 2013-02-13 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子の調節物質
PL1928886T3 (pl) 2005-09-09 2011-09-30 Nerre Therapeutics Ltd Pochodne pirydyny i ich zastosowanie w leczeniu zaburzeń psychotycznych
WO2007039420A1 (en) 2005-09-23 2007-04-12 F. Hoffmann-La Roche Ag Novel dosage formulation
EP1933831A2 (en) 2005-10-06 2008-06-25 Vertex Pharmaceuticals, Inc. Modulators of atp-binding cassette transporters
BRPI0618417A2 (pt) 2005-10-19 2012-07-31 Gruenenthal Chemie novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
DK1945632T3 (da) 2005-11-08 2013-12-16 Vertex Pharma Heterocycliske modulatorer af ATP-bindende kassettetransportører
WO2007054480A1 (en) 2005-11-08 2007-05-18 N.V. Organon 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
US20120232059A1 (en) 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
CN101326182B (zh) 2005-12-05 2011-09-28 史密丝克莱恩比彻姆公司 2-嘧啶基吡唑并吡啶ErbB激酶抑制剂
JP2009521468A (ja) 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
AU2006331565A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in CFTR assays and methods therewith
EP2016065B1 (en) 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
PL1993360T3 (pl) 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007134279A2 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101715450B (zh) 2006-11-03 2013-03-13 沃泰克斯药物股份有限公司 作为cftr调控剂的氮杂吲哚衍生物
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101541759A (zh) 2006-11-27 2009-09-23 诺瓦提斯公司 取代的二氢咪唑类及其在治疗肿瘤中的用途
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2686838C (en) 2007-05-09 2017-03-14 Vertex Pharmaceuticals Incorporated Modulators of cftr
AU2008256717B2 (en) 2007-05-25 2013-11-21 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
DE102007042754A1 (de) 2007-09-07 2009-03-12 Bayer Healthcare Ag Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
NZ620027A (en) 2007-09-14 2015-05-29 Vertex Pharma Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
ES2445442T3 (es) 2007-09-14 2014-03-03 Vertex Pharmaceuticals Inc. Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
FR2921657A1 (fr) 2007-09-28 2009-04-03 Sanofi Aventis Sa Derives de nicotinamide, leur preparation et leur application en therapeutique
DK2578571T3 (en) 2007-11-16 2015-10-05 Vertex Pharma Isoquinoline modulators of ATP binding cassette transporters
CN101998854A (zh) 2007-12-07 2011-03-30 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
DK2639222T3 (en) 2007-12-07 2016-10-03 Vertex Pharma Methods for preparing cycloalkylcarboxamido-pyridinbenzoesyrer
NZ586271A (en) 2007-12-13 2012-08-31 Vertex Pharma Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
WO2009108657A2 (en) 2008-02-28 2009-09-03 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
GB0813709D0 (en) 2008-07-26 2008-09-03 Univ Dundee Method and product
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SMT201800074T1 (it) 2008-08-13 2018-05-02 Vertex Pharma Composizione farmaceutica di n-[2,4-bis(1,1-dimetiletil)-5-idrossifenil]-1,4-diidro-4-ossochinolin-3-carbossammide e sua somministrazione
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2349223A2 (en) 2008-09-29 2011-08-03 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo [d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20110257223A1 (en) 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
HRP20130536T1 (en) 2008-10-23 2013-07-31 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
AU2009308232B2 (en) 2008-10-23 2016-02-04 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN102227424B (zh) 2008-10-23 2013-08-14 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
RS53868B1 (sr) 2008-11-06 2015-08-31 Vertex Pharmaceuticals Incorporated Modulatori atp-vezujućih kasetnih transportera
UA104876C2 (uk) 2008-11-06 2014-03-25 Вертекс Фармасьютікалз Інкорпорейтед Модулятори atф-зв'язувальних касетних транспортерів
EP2382197B1 (en) 2008-12-30 2016-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
HRP20181261T1 (hr) 2009-03-20 2018-12-14 Vertex Pharmaceuticals Incorporated Modulatori regulatora transmembranske provodljivosti cistične fibroze
ES2654414T3 (es) 2009-03-20 2018-02-13 Vertex Pharmaceuticals Incorporated Proceso de preparación de moduladores del regulador de la conductancia transmembrana de la fibrosis quística
DK2427166T3 (da) 2009-05-07 2014-01-27 Gea Pharma Systems Ltd Tabletfremstillingsmodul og fremgangsmåde til kontinuerlig fremstilling af tabletter
JP5793496B2 (ja) 2009-09-17 2015-10-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ アザ二環式化合物を調製するプロセス
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
AU2010310612A1 (en) 2009-10-23 2012-06-14 Vertex Pharmaceuticals Incorporated Process for preparing modulators of cystic fibrosis transmembrane conductance regulator
CA2778493A1 (en) 2009-10-23 2011-04-28 Vertex Pharmaceuticals Incorporated Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US8471029B2 (en) 2010-03-19 2013-06-25 Vertex Pharmaceutical Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20110251253A1 (en) 2010-03-25 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
AU2011242457A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
AU2011242454A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2575814A1 (en) 2010-05-20 2013-04-10 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
TW201202250A (en) 2010-05-20 2012-01-16 Vertex Pharma Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2608779A2 (en) 2010-08-23 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
WO2012027731A2 (en) 2010-08-27 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
EP2452972B2 (de) 2010-11-10 2022-04-13 Continental Reifen Deutschland GmbH Nutzfahrzeugluftreifen
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2773349A1 (en) 2011-11-02 2014-09-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
LT2806859T (lt) 2012-01-25 2019-10-25 Vertex Pharma 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013185112A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Pharmaceuticl compositions for the treatment of cftr -mediated disorders
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
SMT201800590T1 (it) 2012-11-02 2019-01-11 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
ES2702288T3 (es) 2014-10-07 2019-02-28 Vertex Pharma Co-cristales de moduladores de regulador de conductancia transmembrana de la fibrosis quística
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
US10414768B2 (en) 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
EP3250565B1 (en) 2015-01-26 2019-07-03 Rigel Pharmaceuticals, Inc. Tetrazolones as carboxylic acid bioisosteres
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺

Also Published As

Publication number Publication date
EP2789606B1 (en) 2017-11-15
CA2686838C (en) 2017-03-14
JP5497633B2 (ja) 2014-05-21
CN102863432B (zh) 2016-09-07
AU2008251504B2 (en) 2013-07-18
JP2013245219A (ja) 2013-12-09
JP5706485B2 (ja) 2015-04-22
JP2016033162A (ja) 2016-03-10
US20150166516A1 (en) 2015-06-18
US9725440B2 (en) 2017-08-08
HK1138586A1 (en) 2010-08-27
AU2008251504A1 (en) 2008-11-20
CA2686838A1 (en) 2008-11-20
EP2164840A2 (en) 2010-03-24
US20150031708A1 (en) 2015-01-29
CN104447716A (zh) 2015-03-25
WO2008141119A2 (en) 2008-11-20
CN101687842B (zh) 2013-03-06
JP2010526831A (ja) 2010-08-05
EP2789606A1 (en) 2014-10-15
JP5951674B2 (ja) 2016-07-13
JP2014133757A (ja) 2014-07-24
CN101687842A (zh) 2010-03-31
WO2008141119A3 (en) 2009-04-30
US8969386B2 (en) 2015-03-03
CN102863432A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
NZ581259A (en) Modulators of cystic fibrosis transmembrane conductance regulator
NZ600772A (en) Pyridyl derivatives as CFTR modulators
NZ587545A (en) Heteroaryl derivatives as cftr modulators
NZ603044A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
IL257542A (en) Solid forms of (r) –1 (2,2– difluorobenzo [d] [3,1] dioxol – 5-il) - n– (1– (3,2– dihydroxypropyl) –6 – fluoro – 2– (1 –Hydroxy – 2 – methylpropane – 2-il) –1h – indole – 5-il) cyclopropanecarboxamide
ME02650B (me) Modulatori atp- vezujućih kasetnih transportera
NZ746793A (en) Silicone atoms containing ivacaftor analogues
NZ598941A (en) Isoquinoline modulators of ATP-Binding Cassette transporters
IL273752B2 (en) Ingredients, compounds and methods for increasing CFTR activity
ME02105B (me) Modulatori atp-vezujucih kasetnih transportera
HRP20180328T1 (hr) FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
JP2012521361A5 (enExample)
HRP20160682T1 (hr) Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
SI3091011T1 (en) Modulators of ATP conveyor belt conveyors
NZ732701A (en) Compounds, compositions, and methods for increasing cftr activity
RU2010114732A (ru) Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
JP2011516420A5 (enExample)
WO2011116397A1 (en) Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
JP2011505338A5 (enExample)
JP2011513321A5 (enExample)
HRP20140695T1 (hr) Modulatori cistiäśno-fibroznog transmembranskog regulatora provodljivosti
JP2013508407A5 (enExample)
JP2013501787A5 (enExample)
RU2012129206A (ru) Модуляторы атф-связывающих транспортеров
JP2012521362A5 (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3155030, VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MASSACHUSETTS 02210, US

Effective date: 20150127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2016 BY COMPUTER PACKAGES INC

Effective date: 20150418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2017 BY COMPUTER PACKAGES INC

Effective date: 20160419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2019 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20181106

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2023 BY COMPUTER PACKAGES INC

Effective date: 20220417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2024 BY COMPUTER PACKAGES INC

Effective date: 20230417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417